How India's weight-loss drugs could reshape global obesity fight.
No Thumbnail Available
Date
2026-03-19
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Daily Monitor
Abstract
India could soon see wider access to weight-loss drugs following the expiry of a key patent, a move expected to drive down prices and trigger competition among local pharmaceutical firms. The patent on semaglutide-the active ingredient behind Novo Nordisk's popular drugs Wegovy and Ozempic-expires in India this week.
Description
Newspaper Article
Keywords
Citation
Reuters. (2026). How India's weight-loss drugs could reshape global obesity fight. Daily Monitor.